3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
2
Pancreatic Neoplasms
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
venetoclax
28
Rituximab
22
ibrutinib
21
acalabrutinib
21
Cyclophosphamide
20
Specimen Handling
18
obinutuzumab
15
Biopsy
14
fludarabine
13
zanubrutinib
10
pirtobrutinib
10
fludarabine phosphate
9
Magnetic Resonance Spectroscopy
8
Bendamustine Hydrochloride
8
idelalisib
6
Whole-Body Irradiation
6
Mycophenolic Acid
6
Lenalidomide
6
CT-P10
6
ARQ531
6
Cyclosporine
5
Sirolimus
4
Peripheral Blood Stem Cell Transplantation
4
pembrolizumab
3
Vincristine
3
Tacrolimus
3
Prednisone
3
Doxorubicin
3
Disulfides
3
Cyclosporins
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
Maintenance
×
90 days
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled